5 Oversold Biotech Stocks to Invest In Now

4. Akari Therapeutics, plc (NASDAQ:AKTX)

Price Target Upside: 477.59%  

Akari Therapeutics, plc (NASDAQ:AKTX) is among the oversold stocks to invest in.

TheFly reported on April 8 that Maxim Group downgraded AKTX from Buy to Hold and did not assign a price target. The firm pointed to increased financing risk as a key concern, noting ongoing capital requirements and continued pressure on the stock following a ratio change implemented on March 31. It also highlighted a recent selloff after the company’s partnership with WuXi XDC, stating that investor sentiment has been affected by funding uncertainty. With shares trading near record lows and the company’s market value under $5 million, the firm viewed the risk profile as elevated, given a difficult capital-raising environment.

Talking about the WuXi XDC partnership, it was done on April 6. The partnership is intended to accelerate the progress of AKTX-101, the company’s lead antibody-drug conjugate program targeting metastatic urothelial cancer. PH1 is designed as a spliceosome-modulating payload that disrupts RNA splicing in cancer cells while also triggering immune system activity.

Preclinical findings have shown strong tumor reduction and instances of complete remission compared to existing ADC approaches. Akari plans to advance AKTX-101 into a Phase 1 study, with initiation expected in late 2026 or early 2027 pending regulatory clearance.

Akari Therapeutics, plc (NASDAQ:AKTX) is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) using its proprietary RNA splicing–targeting payload platform to treat solid tumors.